Expression of p57kip2, retinoblastoma protein and proliferating cell nuclear antigen in human pancreatic cancer and their relationship with clinicopathology

( views:, downloads: )
Author:
()
()
()
()
()
()
Journal Title:
CHINESE JOURNAL OF PANCREATOLOGY
Issue:
Volume 3, Issue 02, 2003
DOI:
Key Word:

Abstract:

  • [1]Sherr CJ. Cancer cell cycles. Science, 1996, 274: 1672-1677.
  • [2]Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinase(CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors(CKIs). Oncogene, 1995, 11:211-219.
  • [3]Hunter T, Pines J. Cyclins and cancer Ⅱ:cyclins D and CDK inhibitors come of age. Cell, 1994, 79:573-582.
  • [4]Kamb A. Cell-cycle regulators and cancer. Trends Genet, 1995, 11:136-140.
  • [5]Clurman BE, Roberts JM. Cell cycle and cancer. J Natl Cancer Inst, 1995, 87: 1499-1504.
  • [6]Matsuoka S, Edwards MC, Bai C, et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev, 1995, 9: 650-662.
  • [7]Orlow I, Iavarone A, Crider Miller SJ, et al. Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcoma and Wilms' tumor. Cancer Res, 1996, 56:1219-1221.
  • [8]Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev, 1995, 9: 639-649.
  • [9]Kondo M, Matsuoka S, Uchida K, et al. Selective maternal allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. Oncogene, 1996, 12:1365-1368.
  • [10]Matsumoto M, Farihata M, Ohtsuki Y, et al. Immunohistoc-hemical characterization of p57KIP2 expression in human esophageal squamous cell carcinoma. Anticancer Res, 2000, 20:1947-1952.
  • [11]Noura S, Yamamoto H, Sekimoto M, et al. Expression of second class of KIP protein p57KIP2 in human colorectal carcinoma. Int J Oncol, 2001, 19:39-47.
  • [12]Ito Y, Takeda T, Sakon M, et al. Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology, 2001, 61:221-225.
  • [13]Nakai S, Masaki T, Shiratori Y, et al. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival. Int J Oncol, 2002, 20:769-775.
  • [14]Ito Y, Yoshida H, Nakano K, et al. Expression of p57/Kip2 protein in normal and neoplastic thyroid tissues. Int J Mol Med, 2002, 9:373-376.
  • [15]Rosenberg E, Demopoulos RI, Zeleniuch Jacquotte A, et al. Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol, 2001, 32:808-813.
  • [16]Ito Y, Takeda T, Wakasa K, et al. Expression of p57/Kip2 protein in pancreatic adenocarcinoma. Pancreas, 2001, 23:246-250.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn